Intravenous iron sucrose in maintenance dialysis patients with renal anemia: A clinical study

National Medical Journal of China

Volumn 89, Issue 7, 2009, Pages 457-462

  Li, Han ^a   Wang, Shi Xiang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Anemia; Dialysis; Iron; Sucrose

Indexed keywords

C REACTIVE PROTEIN; ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS SUCCINATE; HEMOGLOBIN; PARATHYROID HORMONE; TRANSFERRIN; FERRIC ION; FERRIC OXIDE, SACCHARATED; FERROUS ION;

AGE; ANEMIA; ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FERRITIN BLOOD LEVEL; GASTROINTESTINAL EFFECT; HEMATOCRIT; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; PERITONEAL DIALYSIS; PREMEDICATION; SEX; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL; ADULT; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY ANEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; FEMALE; FERRIC COMPOUNDS; FERROUS COMPOUNDS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 77954895231     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2009.07.006     Document Type: Article

References (22)

1. Portolés J, López-Gómez JM , Aljama P. Anemia management and treatment response in patients on hemodialysis: the MAR study. J Nephrol, 2006, 19: 352-360. (Pubitemid 46785549)
2. Riedel MK, Morqenstern T. Iron replacement in hemodialysis patients with a normal serum ferritin level. Dtseh Med Wochensehr, 2004, 129: 1849-1853. (Pubitemid 39233499)
3. Fishbane S, Kowalski EA. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial, 2000, 13: 381-384.
4. Charytan C, Levin N, Saloum MA. Efficacy and safely of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American Clinical Trial. Am J Kidney Dis, 2001, 37: 300-307. (Pubitemid 32116021)
5. Michael B, Coyne DW, Steven C. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int, 2002, 61: 1830-1839. (Pubitemid 34437938)
6. Brookhart MA, Schneeweiss S, Avorn J, et al. The effect of altitude on dosing and response to erythropoietin in ESRD. J Am Soc Nephrol, 2008, 19: 1389-1395.
7. Riedel MK, Morgenstern T. Iron replacement in hemodialysis patients with a normal serum ferritin level. Dtsch Med Wochenschr, 2004, 129: 1849-1853. (Pubitemid 39233499)
8. Jacobs C, Frei D, Perkins AC. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol Dial Transplant, 2005, 20 Suppl 3: iii3-iii24.
9. Lenga I, Lok C, Murticorena R, et al. Role of oral iron in the management of long-term hemodialysis patients. Clin J Am Soc Nephrol, 2007, 2: 688-693.
10. Rozen-Zvi B, Gafter-Gvili A, Paul M, et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis, 2008, 52: 897-906.
11. Sargent JA, Acchiardo SR. Iron requirements in hemodialysis. Blood Purif, 2004, 22: 112-123.
12. KDOQI, National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis, 2006, 47 Suppl 3: S11-S145.
13. Saadeh CE, Srkalovic G. Acute hypersensitivity reaction to ferric gluconate in a premedicated patient. Ann Pharmacother, 2005, 39: 2124-2127. (Pubitemid 41745962)
14. Hood SA, O'Brien M, Higgins R. The safety of intravenous iron dextran (Dexferrum) during hemodialysis in patients with end stage renal disease. Nephrol Nurs J, 2000, 27: 41-42.
15. McCarthy JT, Regnier CE, Loebertmann CL, et al. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran - a comparison of two products. Am J Nephrol, 2000, 20: 455-462.
16. Anirban G, Kohli HS, Jha V, et al. The comparative safety of various intravenous iron preparations in chronic kidney disease patients. Ren Fail, 2008, 30: 629-638.
17. Reis KA, Guz G, Ozdemir H, et al. Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. Int Heart J, 2005, 46: 255-264.
18. Desai A. Zhao A , Warren JS. Human recombinant crythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice. Nephrol Dial Transplant, 2008, 23: 1513-1520. (Pubitemid 351767760)
19. Rasic-Milutinovic Z, Perunicic G, Pljesa S, et al. Metabolic syndrome in HD patients: association with body composition, nutritional status, inflammation and serum iron. Intern Med, 2007, 46: 945-951. (Pubitemid 47261636)
20. Garneata L. Intravenous iron, inflammation, and oxidative stress: is iron a friend or an enemy of uremic patients? J Ren Nutr, 2008, 18: 40-45.